Skip to main content
Figure 8 | Molecular Medicine

Figure 8

From: Hematopoietic CC-Chemokine Receptor 2 (CCR2) Competent Cells Are Protective for the Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimer’s Disease

Figure 8

CCR2−/− BMC transplantation in APPSwe/PS1 mice reduces monocyte frequencies and inverses the ratio of Gr1+/Gr1 monocytes, as observed in CCR2−/− and APPSwe/PS1/CCR2−/− mice. Whole blood was taken and stained with fluorescent antibodies for CD11b, CD115 and Gr1 and analyzed by FACS in 4-month-old WT, CCR2−/−, APPSwe/PS1/CCR2−/− mice and APPSwe/PS1 mice harboring WT or CCR2−/− BMCs. Monocytes were characterized by CD11b and CD115 expression (A). Percentages of monocytes in leukocytes were quantified (B). Gr1 expression was assessed in monocytes. The percentage of Gr1+ or Gr1 monocytes was determined in monocytes and in leukocytes (D). Monocyte frequencies were drastically decreased in CCR2−/−, APPSwe/PS1/CCR2−/− mice and APPSwe/PS1 mice harboring CCR2−/− BMCs. In contrast, APPSwe/PS1 mice harboring WT BMCs had higher level of monocytes, as observed in WT and APPSwe/PS1 mice. CCR2−/−, APPSwe/PS1/CCR2−/− mice and APPSwe/PS1 mice harboring CCR2−/− BMCs exhibited similarly decreased levels of Gr1+ and Gr1 monocytes. Each graph shows a representative example of each group. Numbers near boxes indicate the percentage of CD11b+ CD115+ cells (A) and Gr1+ or Gr1 monocytes (C) for this example. Results are expressed as the mean ± SEM; n = 3−4; *P < 0.05, **P < 0.01 and ***P < 0.001 versus WT mice; ###P < 0.001 versus WT → APPSwe/PS1 mice; °P < 0.05 and °°°P < 0.001 versus APPSwe/PS1 mice. One-way ANOVA using Bonferroni or Tamhane post hoc tests was performed. □, WT; , WT → APPSwe/PS1; ■, APPSwe/PS1; , CCR2−/−; , APPSwe/PS1/CCR2−/−; , CCR2−/− → APPSwe/PS1.

Back to article page